{"id":800948,"date":"2025-01-15T08:03:51","date_gmt":"2025-01-15T13:03:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/"},"modified":"2025-01-15T08:03:51","modified_gmt":"2025-01-15T13:03:51","slug":"envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/","title":{"rendered":"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>ENVISION Trial Results Published in the February Issue of <i>The Journal of Urology<\/i> Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile<\/p>\n<\/li>\n<\/ul>\n<p>PRINCETON, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) were published in the February issue of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.auajournals.org%2Fdoi%2F10.1097%2FJU.0000000000004296&amp;esheet=54180006&amp;newsitemid=20250115929797&amp;lan=en-US&amp;anchor=The+Journal+of+Urology&amp;index=1&amp;md5=45dddb06f66d1cd53513343d492a0608\"><i>The Journal of Urology<\/i><\/a><i>.<\/i><\/p>\n<p>\nIn the ENVISION trial, UGN-102 treatment demonstrated an impressive 82.3% (95% CI, 75.9%, 87.1%) 12-month duration of response (DOR) by Kaplan-Meier estimate (n=108) in patients who achieved a CR at three months after the first instillation of UGN-102 (mitomycin) for intravesical solution. The Kaplan-Meier estimates for DOR at 15 months (n=43) and 18 months (n=9) following the 3-month CR were both 80.9% (95% CI, 73.9%, 86.2%). The ENVISION trial also met its primary endpoint, showing a 79.6% (95% CI, 73.9%, 84.5%) CR rate at three months in patients treated with UGN-102.<\/p>\n<p>\n\u201cThese data from the ENVISION trial provide compelling evidence that treatment with UGN-102 achieves a clinically meaningful complete response rate and also demonstrates remarkable durability in patients with LG-IR-NMIBC,\u201d said Sandip Prasad, MD, M.Phil., Director of Genitourinary Surgical Oncology at Morristown Medical Center\/Atlantic Health System, NJ, and Principal Investigator of the ENVISION trial. \u201cThe long-term results, with 82.3% duration of response at 12 months, further strengthen UGN-102\u2019s potential as a non-surgical, effective treatment for patients facing the recurrent and challenging nature of LG-IR-NMIBC.\u201d<\/p>\n<p>\nAccording to Mark Schoenberg, M.D., Chief Medical Officer, UroGen, &#8220;The impressive duration of response data from the ENVISION trial further highlights UGN-102\u2019s potential to transform the treatment landscape for patients with LG-IR-NMIBC. Many of these patients are elderly and face the burden of repeated surgeries under general anesthesia, so there is a critical need for innovative treatment options for this patient population. We believe that, if approved, UGN-102\u2019s ability to achieve durable complete responses and potentially reduce recurrence rates while extending treatment-free intervals will represent a significant advance in managing LG-IR-NMIBC.\u201d<\/p>\n<p>\nUroGen initiated the submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UGN-102 as a treatment for LG-IR-NMIBC in January 2024 and completed the NDA submission in August, ahead of schedule. The FDA accepted the NDA for UGN-102 with a PDUFA goal date of June 13, 2025.<\/p>\n<p>\nThe most common treatment-emergent adverse events (TEAEs) in the ENVISION trial were dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention. The TEAEs were typically mild-to-moderate in severity and either resolved or were resolving. The ENVISION trial demonstrated a similar safety profile to that observed in other studies of UGN-102.<\/p>\n<p><b>About UGN-102<\/b><\/p>\n<p>\nUGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently in Phase 3 development for the treatment of LG-IR-NMIBC. Utilizing UroGen\u2019s proprietary <i>RTGel<\/i>\u00ae technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting by a trained healthcare professional. UroGen completed the NDA submission in August, ahead of schedule. The FDA accepted the NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025.<\/p>\n<p><b>About Non-Muscle Invasive Bladder Cancer (NMIBC)<\/b><\/p>\n<p>\nIn the U.S., bladder cancer is the second most common urologic cancer in men. LG-IR- NMIBC represents approximately 23,000 newly diagnosed bladder cancer patients each year and an estimated 59,000 recurrences annually among patients diagnosed from previous years. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include trans-urethral resection of bladder tumor (TURBT) as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures.<\/p>\n<p><b>About ENVISION<\/b><\/p>\n<p>\nThe Phase 3 ENVISION trial is a single-arm, multinational, multicenter study evaluating the efficacy and safety of UGN-102 (mitomycin) for intravesical solution as a chemoablative therapy in patients with LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with approximately 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of UGN-102. The primary endpoint evaluated the CR rate at the three-month assessment after the first instillation, and the key secondary endpoint evaluated durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=54180006&amp;newsitemid=20250115929797&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=2&amp;md5=cc41a5f4d91bd429b0e1a1977013edb2\">www.clinicaltrials.gov<\/a> (NCT05243550).<\/p>\n<p><b>About UroGen Pharma Ltd.<\/b><\/p>\n<p>\nUroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed <i>RTGel <\/i>reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen\u2019s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.urogen.com&amp;esheet=54180006&amp;newsitemid=20250115929797&amp;lan=en-US&amp;anchor=www.UroGen.com&amp;index=3&amp;md5=2febf32acc3aca8acc9c91b5dc2e4597\">www.UroGen.com<\/a> to learn more or follow us on X (Twitter), @UroGenPharma.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for UGN-102 as the first FDA-approved non-surgical treatment for LG-IR-NMIBC; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential benefits to patients and opportunities for UGN-102, if approved, including to transform the treatment landscape for patients with LG-IR-NMIBC; statements related to UroGen\u2019s NDA submission and expected PDUFA target action date for UGN-102 and the potential approval and timing thereof; the potential of UroGen\u2019s proprietary <i>RTGel <\/i>technology to improve therapeutic profiles of existing drugs; and UroGen\u2019s sustained release technology making local delivery potentially more effective as compared to other treatment options. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: even though the NDA for UGN-102 has been accepted for filing by the FDA, there is no guarantee that such NDA will be sufficient to support approval of UGN-102 on the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen\u2019s industry; the scope, progress and expansion of developing and commercializing UroGen\u2019s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-\u00e0-vis alternative therapies; UroGen\u2019s ability to attract or retain key management, members of the board of directors and other personnel; UroGen\u2019s <i>RTGel<\/i> technology may not perform as expected; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates <i>RTGel <\/i>technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024 (which is available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54180006&amp;newsitemid=20250115929797&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=96c663b5653c295c9be70f1f435e4cf9\">www.sec.gov<\/a>), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen\u2019s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250115929797\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250115929797\/en\/<\/a><\/span><\/p>\n<p><b>INVESTOR CONTACT:<br \/>\n<br \/><\/b>Vincent Perrone<br \/>\n<br \/>Senior Director, Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:vincent.perrone@urogen.com\">vincent.perrone@urogen.com<br \/>\n<\/a><br \/>609-460-3588 ext. 1093<\/p>\n<p><b>MEDIA CONTACT:<br \/>\n<\/b><br \/>Cindy Romano<br \/>\n<br \/>Director, Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cindy.romano@urogen.com\">cindy.romano@urogen.com<br \/>\n<br \/><\/a>609-460-3583 ext. 1083<\/p>\n<p><b>KEYWORDS:<\/b> New Jersey United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250115929797\/en\/2353549\/3\/UroGen_logo2_%28R%29_%28002%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211; UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) were published in the February &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-800948","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211; UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) were published in the February &hellip; Continue reading &quot;ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-15T13:03:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025\",\"datePublished\":\"2025-01-15T13:03:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/\"},\"wordCount\":1391,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/\",\"name\":\"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-01-15T13:03:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/","og_locale":"en_US","og_type":"article","og_title":"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Market Newsdesk","og_description":"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211; UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) were published in the February &hellip; Continue reading \"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-15T13:03:51+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025","datePublished":"2025-01-15T13:03:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/"},"wordCount":1391,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/","name":"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-01-15T13:03:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250115929797r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/envision-trial-results-published-in-the-february-issue-of-the-journal-of-urology-highlight-ugn-102-achievement-of-82-3-duration-of-response-at-12-months-paving-the-way-for-the-potential-first-fda-appr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=800948"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800948\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=800948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=800948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=800948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}